Drug intelligence / Profile preview

TTX-mRNA

Development stage: Unknown
Lead developer: TransCode Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**TTX-mRNA** is an investigational messenger RNA-based therapeutic platform developed by TransCode Therapeutics for oncology applications. It leverages the company's proprietary TTX nanoparticle delivery system to enable targeted delivery of mRNA payloads to cancer cells, aiming to address unmet needs in cancer treatment through precision RNA therapeutics.[17][18]

Beyond the preview

Go deeper on TTX-mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTX-mRNA.

Explore the full profile